---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-21-235830"
form_type: "8-K"
ticker: "FATE"
cik: "0001434316"
company_name: "FATE THERAPEUTICS INC"
filed_at: "2021-08-04T23:59:59+00:00"
generated_at: "2026-06-29T22:29:50.158233+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# Fate Therapeutics appoints Yuan Xu, Ph.D. to Board of Directors

## Summary
- Board expanded from 9 to 10 directors; Yuan Xu appointed as Class II director effective August 3, 2021.
- Dr. Xu granted option to purchase 7,501 shares and RSUs for 4,744 shares, vesting over 3 years.
- Dr. Xu previously CEO of Legend Biotech, led cilta-cel development and partnership with Janssen.
- Over 25 years biopharma experience including senior roles at Merck, Gilead, and Novartis.

## SEC filing metadata
- accession: 0001193125-21-235830
- form_type: 8-K
- ticker: FATE
- cik: 0001434316
- company_name: FATE THERAPEUTICS INC
- filed_at: 2021-08-04T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1434316/000119312521235830/0001193125-21-235830-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1434316/000119312521235830/d213764d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-21-235830
- JSON: https://secwatch.observer/filing/0001193125-21-235830.json
- Plain text: https://secwatch.observer/filing/0001193125-21-235830.txt

## Key facts
- Executive change
  Yuan Xu was appointed as Class II director at FATE THERAPEUTICS INC.
  - Action: appointed
  - Role: Class II director
  source text: On August 3, 2021, the Board appointed Yuan Xu, Ph.D. to the Board as a Class II director.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1434316/000119312521235830/0001193125-21-235830-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.